<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Currently there is no effective treatment for nonalcoholic <z:hpo ids='HP_0001397'>fatty liver</z:hpo> disease (NAFLD), especially <z:hpo ids='HP_0001395'>hepatic fibrosis</z:hpo> induced by type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="9927">Valsartan</z:chebi> maybe has beneficial effect on the <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of the present study was to investigate the effect of <z:chebi fb="0" ids="9927">valsartan</z:chebi> on the pathological progression of <z:hpo ids='HP_0001395'>hepatic fibrosis</z:hpo> in rats with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>An animal model of <z:hpo ids='HP_0001395'>hepatic fibrosis</z:hpo> with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> was developed using a high-<z:chebi fb="27" ids="17992">sucrose</z:chebi>, high-fat diet and low-dose <z:chebi fb="1" ids="9288">streptozotocin</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="9927">Valsartan</z:chebi> (15 mg/kg/day, i.g.) was orally administered for four months </plain></SENT>
<SENT sid="5" pm="."><plain>The livers were removed to make <z:chebi fb="1" ids="51686">hematoxylin</z:chebi>-eosin (HE) staining and <z:chebi fb="1" ids="46149">Picric acid</z:chebi>-Sirius red staining, and immunohistochemistry staining of α-smooth-muscle-actin (α-SMA), transforming growth factor β1 (TGF-β1), <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF-α) and monocyte chemotactic protein-1 (<z:chebi fb="17" ids="50099">MCP</z:chebi>-1) </plain></SENT>
<SENT sid="6" pm="."><plain>Terminal deoxynucleotidyl transferase-mediated <z:chebi fb="0" ids="17625">dUTP</z:chebi> nick end labeling (TUNEL) staining was performed to detect hepatocyte <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>The liver mitochondria were isolated to measure the <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> respiratory function </plain></SENT>
<SENT sid="8" pm="."><plain>The results showed that <z:chebi fb="0" ids="9927">valsartan</z:chebi> significantly alleviated the lesion of <z:hpo ids='HP_0001397'>hepatic steatosis</z:hpo> and <z:hpo ids='HP_0001395'>hepatic fibrosis</z:hpo> by HE staining and <z:chebi fb="1" ids="46149">Picric acid</z:chebi>-Sirius red staining </plain></SENT>
<SENT sid="9" pm="."><plain>Immunohistochemical staining suggested that the expression of α-SMA, TGF-β1, TNF-α and <z:chebi fb="17" ids="50099">MCP</z:chebi>-1 in liver tissue of diabetic rats was markedly reduced by <z:chebi fb="0" ids="9927">valsartan</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>TUNEL staining showed that there were fewer TUNEL-positive apoptotic hepatocytes in <z:chebi fb="0" ids="9927">valsartan</z:chebi> group </plain></SENT>
<SENT sid="11" pm="."><plain>In addition, <z:chebi fb="0" ids="9927">valsartan</z:chebi> restored the injured hepatic <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> respiratory function </plain></SENT>
<SENT sid="12" pm="."><plain>The findings demonstrated that <z:chebi fb="0" ids="9927">valsartan</z:chebi> prevented the pathological progression of <z:hpo ids='HP_0001395'>hepatic fibrosis</z:hpo> in type 2 diabetic rats, correlated with reducing α-SMA, TGF-β1, TNF-α and <z:chebi fb="17" ids="50099">MCP</z:chebi>-1 expression, also anti-<z:mpath ids='MPATH_3'>apoptosis</z:mpath> and mitochondria-protective potential </plain></SENT>
</text></document>